Thermo Fisher Scientific (TMO) Is Building A Bigger Role In Precision Diagnostics

Thermo Fisher Scientific (NYSE:TMO) is expanding its presence in proteomic biomarker analytics and immuno-oncology diagnostics, according to recent industry reports. Sector intelligence points to the group as a key provider of targeted omics and biomarker analytics solutions for precision medicine-focused projects. Reports also highlight Thermo Fisher's role in immuno-oncology diagnostic workflows that support more tailored cancer treatment decisions. Thermo Fisher's push into proteomic...